Turning Point Therapeutics, Inc. TPTX
At closeAug 15, 2022, 4:00 PM EDT
52-week range unavailable
- Revenue (ttm)
- 1.01M
- Shares out
- 50.07M
- Forward P/E
- -10.54
- Volume
- 1.03M
- Open
- 75.32
- Previous close
- 75.49
- Day's range
- 75.30 – 75.77
- Beta
- -0.19
- Analysts
- Hold
- Price target
- 71.50 (-5.3%)
- Earnings date
- Aug 8, 2022
Key statistics
- Enterprise value
- 2.99B
- PEG ratio
- 0.00
- Price / sales
- 3775.94
- Price / book
- 4.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -97.70%
- Free cash flow
- -136.76M
- Total cash
- 818.29M
- Total debt
- 4.94M
- Return on equity
- -36.80%
- Short % of float
- 4.51%
- 50-day average
- 75.21
- 200-day average
- 46.90
Analyst view
Consensus: hold
- Target (low)
- 58.00
- Target (mean)
- 71.50
- Target (high)
- 76.00
- Strong buy1
- Buy0
- Hold8
- Sell0
- Strong sell0
Next earnings
Aug 8, 2022
Expected Aug 8, 2022. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2022 | Jun 1, 2022 | -1.78 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -1.45 | — | — | — |
| Feb 28, 2022 | Dec 1, 2021 | -1.40 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -1.26 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | -1.20 | — | — | — |
| May 5, 2021 | Mar 1, 2021 | -0.58 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2022 | SVB Leerink | down | Outperform | Market Perform |
| Jun 6, 2022 | Cowen & Co. | down | Outperform | Market Perform |
| Jun 6, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Jun 3, 2022 | Wedbush | down | Outperform | Neutral |
| May 24, 2022 | Goldman Sachs | main | — | Buy |
| May 20, 2022 | B of A Securities | init | — | Buy |
About Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. As of August 15, 2022, Turning Point Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tptherapeutics.com
News
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May 
Stocks That Hit 52-Week Lows On Monday 
Stocks That Hit 52-Week Lows On Friday 
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 - The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
- Earnings Scheduled For November 9, 2021
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021 
Earnings Scheduled For August 9, 2021 - Earnings Scheduled For May 5, 2021
Earnings Scheduled For March 1, 2021
Your note
Sign in to keep a note on TPTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLES MARK J | Director | Purchase | Jun 20, 2021 | 2,000 |
| BAKER BRIAN LEE | Officer | Sale | Mar 22, 2021 | 4,116 |
| COUNTOURIOTIS ATHENA M | Chief Executive Officer | Stock Award(Grant) | Feb 8, 2022 | 110,330 |
| HIRMAND MOHAMMAD | Officer | Stock Award(Grant) | Feb 8, 2022 | 40,821 |
| NORTH ANNETTE | General Counsel | Stock Award(Grant) | Feb 8, 2022 | 27,979 |
| PARTRIDGE ANDREW JOHN | Officer | Stock Award(Grant) | Feb 8, 2022 | 38,361 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 8.30% | 4,157,552 | 316.02M | Jun 29, 2022 |
| Blackrock Inc. | 7.57% | 3,791,801 | 288.21M | Jun 29, 2022 |
| Cormorant Asset Management, LP | 4.96% | 2,484,220 | 188.83M | Jun 29, 2022 |
| Federated Hermes, Inc. | 4.14% | 2,075,037 | 157.72M | Mar 30, 2022 |
| AllianceBernstein, L.P. | 4.06% | 2,035,049 | 154.68M | Mar 30, 2022 |
| Orbimed Advisors LLC. | 4.02% | 2,012,250 | 152.95M | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | 2.59% | 1,296,184 | 98.52M | Apr 29, 2022 |
| Price (T.Rowe) New Horizons Fund | 2.51% | 1,259,029 | 95.70M | Mar 30, 2022 |
| Vanguard Total Stock Market Index Fund | 2.32% | 1,150,487 | 87.45M | Mar 30, 2022 |
| iShares Russell 2000 ETF | 2.08% | 1,033,004 | 78.52M | Jun 29, 2022 |
| Federated Hermes Kaufmann Small Cap Fund | 2.03% | 1,015,600 | 77.20M | Apr 29, 2022 |
| Federated Hermes Kaufmann Fund | 2.00% | 1,000,000 | 76.01M | Apr 29, 2022 |